Form 4: Vor Biopharma CEO Robert Ang Reports Stock Option Repricing and RSU Grant

Robert Ang, CEO of Vor Biopharma, reports the repricing of stock options and the grant of restricted stock units (RSUs) in a recent SEC filing.

Summary

• On February 3, 2025, Vor Biopharma's CEO, Robert Ang, reported changes in his beneficial ownership of the company's stock.
• The reported transactions include the withholding of 3,248 common stock shares to cover tax obligations related to the settlement of restricted stock units (RSUs) at a price of $1.34.
• Ang also acquired 137,500 shares underlying RSUs, which vest in equal quarterly installments over four years starting February 1, 2025.
• Additionally, the company's Board of Directors approved a stock option award repricing, effective February 3, 2025, under the 2015 Stock Incentive Plan, 2021 Equity Incentive Plan, and 2023 Inducement Plan.
• The exercise price for the repriced stock options is $1.34 per share, reflecting the fair market value on the effective date.
• The repriced stock options will revert to their original exercise price if exercised during the Retention Period, which ends 12 months after the effective date, upon a Change in Control, or 30 days before the option's original expiration date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The repricing of stock options and granting of RSUs are standard practices to incentivize management, suggesting confidence in the company's future. However, the retention period on the repriced options introduces a conditional element.

Positives

• The repricing of stock options at the current fair market value could incentivize the CEO to improve company performance.
• The granting of RSUs aligns the CEO's interests with those of shareholders, as the value of the RSUs is tied to the company's stock price.

Risks

• The repriced stock options could revert to their original exercise price if exercised during the Retention Period, potentially diluting shareholder value if the original price was significantly higher.
• The vesting schedule of the RSUs is contingent upon the CEO's continued service, creating a potential risk if the CEO were to leave the company before the RSUs fully vest.

Future Outlook

The RSUs vest over four years, and the repriced stock options have a retention period that could affect their exercise price, influencing the CEO's long-term incentives.

Industry Context

Stock option repricing and RSU grants are common practices in the biopharmaceutical industry to incentivize and retain key executives, especially in companies with long development timelines and high risk.

Comparison to Industry Standards

• Comparing Vor Biopharma's executive compensation practices to similar-stage biotech companies like CRISPR Therapeutics or Editas Medicine would provide a benchmark for assessing the competitiveness and appropriateness of the stock option repricing and RSU grant.
• Industry standards often involve a mix of salary, stock options, and RSUs, with the proportion of each varying based on company size, stage of development, and performance metrics.
• The vesting schedules and retention periods associated with these equity grants are also important factors to consider when comparing Vor Biopharma's practices to those of its peers.

Stakeholder Impact

• Shareholders may be impacted by potential dilution from the exercise of stock options.
• Employees may be affected by the overall compensation structure and incentives provided to management.

Key Dates

Keywords

stock options, RSU, repricing, beneficial ownership, Form 4, Vor Biopharma, Robert Ang